Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OSI-906 and Endocrine Therapy in Hormone-Sensitive Metastatic Breast Cancer
NCT01013506Phase 2Withdrawn
- Sponsor
- Vanderbilt-Ingram Cancer Center
- Start
- Aug 2009
- Primary completion
- Dec 2009
01
Overview
Phase 2, open-label trial of linsitinib in breast cancer, sponsored by Vanderbilt-Ingram Cancer Center. Planned start Aug 2009; status: withdrawn.
02
Drugs
linsitinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01013506.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01013506.